title: Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor.
abstract: The inhibitory receptor Ig-like transcript (ILT)2 (leukocyte Ig-like receptor or CD85j) is a type I transmembrane protein expressed by different leukocyte lineages. The extracellular region of ILT2 binds HLA class I molecules, and its cytoplasmic domain displays four immunoreceptor tyrosine-based inhibition motifs. Upon tyrosine phosphorylation ILT2 recruits the Src homology 2 domain-containing protein tyrosine phosphatase 1 (SHP-1) that is involved in negative signaling. To address the structural basis of ILT2-mediated inhibitory signaling, deletion and single tyrosine mutants were generated and transfected in the COS-7 and rat basophilic leukemia cell lines; their abilities to bind SHP-1 and to inhibit FcepsilonR-induced serotonin release in rat basophilic leukemia cells were studied. Both biochemical and functional analyses revealed tyrosines 644 (SIYATL) and 614 (VTYAQL) as the SHP-1 docking sites required for ILT2 inhibitory function. Substitution of tyrosine 562 (VTYAEV) did not alter receptor function. By contrast, mutation of tyrosine 533 (NLYAAV) interfered with ILT2 tyrosine phosphorylation and the subsequent SHP-1 recruitment, thus supporting a regulatory role for this motif.
authors.affiliation: Hospital de la Princesa, Madrid, Spain.
authors.forename: Teresa
authors.initials: T
authors.lastname: Bellón
authors.forename: Friederike
authors.initials: F
authors.lastname: Kitzig
authors.forename: Joan
authors.initials: J
authors.lastname: Sayós
authors.forename: Miguel
authors.initials: M
authors.lastname: López-Botet
mesh_terms: D020816:Amino Acid Motifs / Q000235:genetics / Q000276:immunology; D000818:Animals; D015703:Antigens, CD / Q000235:genetics* / Q000378:metabolism* / Q000502:physiology; D019556:COS Cells; D002461:Cell Line, Transformed; D002478:Cells, Cultured; D018920:Coculture Techniques; D003593:Cytoplasm / Q000201:enzymology / Q000235:genetics / Q000378:metabolism; D004252:DNA Mutational Analysis; D004792:Enzyme Precursors / Q000378:metabolism; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D000075362:Leukocyte Immunoglobulin-like Receptor B1; D008024:Ligands; D010766:Phosphorylation; D011485:Protein Binding / Q000235:genetics; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D051381:Rats; D017455:Receptors, IgE / Q000037:antagonists & inhibitors / Q000502:physiology; D011971:Receptors, Immunologic / Q000235:genetics* / Q000378:metabolism* / Q000502:physiology; D012702:Serotonin Antagonists / Q000378:metabolism / Q000494:pharmacology; D000072377:Syk Kinase; D014407:Tumor Cells, Cultured; D014443:Tyrosine / Q000235:genetics* / Q000378:metabolism; D018909:src Homology Domains / Q000235:genetics
chemical_list: D015703:Antigens, CD; D004792:Enzyme Precursors; D047908:Intracellular Signaling Peptides and Proteins; C105299:LILRB1 protein, human; D000075362:Leukocyte Immunoglobulin-like Receptor B1; D008024:Ligands; D017455:Receptors, IgE; D011971:Receptors, Immunologic; D012702:Serotonin Antagonists; D014443:Tyrosine; D011505:Protein-Tyrosine Kinases; C000606896:SYK protein, human; D000072377:Syk Kinase; C000606898:Syk protein, rat